Skip to main content

Featured

FS visits biomedical firm in UK

Financial Secretary Paul Chan yesterday visited a biopharmaceutical company and the Royal College of Art, and attended a lunch hosted by the China-Britain Business Council, as part of his ongoing trip to London.   Mr Chan visited AstraZeneca and met the company’s senior management to learn about its drug research and development activities, as well as its latest expansion plans.   AstraZeneca indicated that following in-depth talks with Hong Kong’s Office for Attracting Strategic Enterprises, it plans to develop a research and development centre in Hong Kong and will engage in further discussion with relevant government departments on the matter.   The Financial Secretary then attended a roundtable luncheon held by the China-Britain Business Council, and met representatives of British enterprises that do business, or plan to do business, either in the Mainland or Hong Kong.   Mr Chan later visited the Royal College of Art, which collaborated with the Hong Kong Polytechnic Unive
Read more

Vaccine recommendations published

The two scientific committees under the Centre for Health Protection convened a meeting today to provide recommendations on the use of COVID-19 vaccination for those with previous COVID-19 infection.   Joined by the Chief Executive’s expert advisory panel, the committees also discussed the existing evidence on COVID-19 vaccine effectiveness against different variants.       The meeting noted that previous COVID-19 infection usually confers immunity for at least six to nine months for the majority of patients. There is accumulating evidence showing that those previously infected with COVID-19 would be further protected by one dose of mRNA vaccines.   After receiving one dose of mRNA vaccine, these people may experience more systemic side effects, such as fatigue, headache, chills, muscle pain, fever and joint pain, when compared to those without prior infection.   People who wish to receive the mRNA vaccine should wait for at least 90 days after discharge from previous infection.   The meeting also noted that in general, studies have shown that the existing vaccines work well against the non-variant. The effectiveness data against variants differ by vaccines.   The Fosun Pharma/BioNTech vaccine is effective against the variants which first emerged in the UK and Brazil, but is less effective against the South African one.   There is currently limited efficacy data of CoronaVac developed by Sinovac Biotech (Hong Kong) against variants.   The vaccine developed by AstraZeneca in collaboration with the University of Oxford is effective against the UK variants but is ineffective against the South African one.   The meeting also agreed that the combination of non-pharmaceutical interventions with vaccination will allow for maximum protection against the virus. There is a need to continue social distancing, good hand hygiene and wearing a mask in public to reduce the risk of transmission.
http://dlvr.it/RvxZ2z

Popular Posts